FWP
EW icon

Forefront Wealth Partners’s Edwards Lifesciences EW Stock Holding History

Forefront Wealth Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,492
Closed -$349K – 157
2025
Q3 		$349K Buy
+4,492
New +$351K 0.09% 148

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Forefront Wealth Partners's EW Position: Q4 2025 in Review

Forefront Wealth Partners sold out of Edwards Lifesciences (EW) in Q4 2025, closing a stake of 4,492 shares — an estimated $349K sold.

Forefront Wealth Partners first reported a position in EW in Q3 2025 and held it in 1 quarter. The position peaked at $349K in Q3 2025. 1,313 funds tracked by Wall St. Rank hold EW as of Q4 2025.

  • Forefront Wealth Partners reported no remaining Edwards Lifesciences position as of Q4 2025 after selling out during the quarter.
  • Forefront Wealth Partners sold 4,492 Edwards Lifesciences shares in Q4 2025, an estimated $349K.
  • Forefront Wealth Partners first reported a position in Edwards Lifesciences in Q3 2025 and held it in 1 quarter.
  • Forefront Wealth Partners's Edwards Lifesciences position peaked at $349K in Q3 2025.
  • 1,313 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2025.

Based on Forefront Wealth Partners's 13F filing for Q4 2025, filed 6 Feb 2026.